Staffing and training are not just operational issues. They are inspection risks. In this episode, we break down what sponsors and regulators actually expect when it comes to site staff training. Competent staff is not enough if training is not documented. We walk through common failure points seen during FDA inspections, including missing GCP documentation, unclear staff roles, and poor escalation processes. We also discuss how structured SOPs, training logs, and clear contracts with coordinators and sub-investigators help demonstrate a real culture of compliance. The goal is simple. When sponsors or the FDA review your site, your records should tell a clear, defensible story.

Key Topics Covered

• GCP training and documentation expectations
• Why undocumented training creates inspection risk
• Common staffing failures seen during FDA inspections
• Training SOPs and staff training logs
• Defining roles and liability in staff contracts
• Managing protocol deviations and escalation paths
• Demonstrating a culture of compliance at the site level

Who This Is For

• Clinical trial sites
• Sponsors and CROs
• Principal Investigators
• Study coordinators
• Clinical operations leaders

Support the show

www.kulkarnilawfirm.com

Early termination by a sponsor can leave a clinical research site holding the bill for prep work, fees, and staffing. In this episode, Darshan explains the contract language every site should insist on to stay protected. He covers guaranteed payment for all work performed up to the termination date, reimbursement for non-cancelable expenses like IRB fees and advertising, and why a wind-down clause is essential for chart reviews, final visits, and data queries. He also explores when minimum payments or upfront funds are realistic to request. Protecting these terms upfront keeps an unexpected sponsor exit from destabilizing your operations. If you have question, Call 302.252.6959, click www.kulkarnilawfirm.com , or email darshan@Kulkarnilawfirm.com.

Support the show

www.kulkarnilawfirm.com

Your skincare product may look like a cosmetic, but one wrong claim can legally turn it into an unapproved drug.

In this episode of KLF Deep Dive, we break down the exact words, phrases, and influencer mistakes that push cosmetic brands straight into FDA drug territory. Anti-inflammatory claims. Acne treatment language. Collagen rebuilding promises. Detox buzzwords. These are not harmless marketing fluff. They are regulatory landmines.

We explain how the FDA actually classifies products, why intent does not matter, how influencers can sink your brand, and what cosmetic companies should do right now to stay compliant.

If you work in beauty, skincare, or wellness marketing, this episode can save your next launch.

If compliance, enforcement, or deals matter to your business, subscribe to KLF Deep Dive.

Support the show

www.kulkarnilawfirm.com